Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort
-
- M. Matejcic
- International Agency for Research on Cancer Lyon France
-
- F. Lesueur
- Genetic Epidemiology of Cancer team, Inserm, U900 Paris France
-
- C. Biessy
- International Agency for Research on Cancer Lyon France
-
- A.L. Renault
- Genetic Epidemiology of Cancer team, Inserm, U900 Paris France
-
- N. Mebirouk
- Genetic Epidemiology of Cancer team, Inserm, U900 Paris France
-
- S. Yammine
- International Agency for Research on Cancer Lyon France
-
- P. Keski‐Rahkonen
- International Agency for Research on Cancer Lyon France
-
- K. Li
- International Agency for Research on Cancer Lyon France
-
- B. Hémon
- International Agency for Research on Cancer Lyon France
-
- E. Weiderpass
- Genetic Epidemiology Group Folkhälsan Research Center Helsinki Finland
-
- V. Rebours
- Department of Gastroenterology and Pancreatology Beaujon Hospital, University Paris 7 Clichy France
-
- M.C. Boutron‐Ruault
- INSERM, Centre for Research in Epidemiology and Population Health U1018, Health across Generations Team, Institut Gustave Roussy Villejuif France
-
- F. Carbonnel
- INSERM, Centre for Research in Epidemiology and Population Health U1018, Health across Generations Team, Institut Gustave Roussy Villejuif France
-
- R. Kaaks
- Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg Germany
-
- V. Katzke
- Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg Germany
-
- T. Kuhn
- Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg Germany
-
- H. Boeing
- Epidemiology German Institute of Human Nutrition Potsdam‐Rehbruecke (DIfE) Nuthetal Germany
-
- A. Trichopoulou
- Hellenic Health Foundation Athens Greece
-
- D. Palli
- Molecular and Nutritional Epidemiology Unit Cancer Research and Prevention Institute – ISPO Florence Italy
-
- C. Agnoli
- Epidemiology and Prevention Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
-
- S. Panico
- Clinical Medicine and Surgery Department Università degli Studi di Napoli Federico II Naples Italy
-
- R. Tumino
- Cancer Registry and Histopathology Department ASP "Civic ‐ M.P. Arezzo" Hospital Ragusa Italy
-
- C. Sacerdote
- Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital, University of Turin and Centre for Cancer Prevention (CPO) Turin Italy
-
- J.R. Quirós
- EPIC Asturias, Public Health Directorate Asturias Spain
-
- E.J. Duell
- Unit of Nutrition and Cancer Catalan Institute of Oncology (ICO‐IDIBELL) Barcelona Spain
-
- M. Porta
- Hospital del Mar Research Institute – IMIM CIBER Epidemiología y Salud Pública (CIBERESP) and Universitat Autònoma de Barcelona Barcelona Spain
-
- M.J. Sánchez
- Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada Granada Spain
-
- M.D. Chirlaque
- CIBER in Epidemiology and Public Health (CIBERESP) Madrid Spain
-
- A. Barricarte
- CIBER in Epidemiology and Public Health (CIBERESP) Madrid Spain
-
- P. Amiano
- Public Health Division of Gipuzkoa BioDonostia Research institute San Sebastian Spain
-
- W. Ye
- Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden
-
- P.H. Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht The Netherlands
-
- K.T. Khaw
- University of Cambridge School of Clinical Medicine Cambridge United Kingdom
-
- A. Perez‐Cornago
- Cancer Epidemiology Unit Nuffield Department of Population Health, University of Oxford Oxford United Kingdom
-
- T.J. Key
- Cancer Epidemiology Unit Nuffield Department of Population Health, University of Oxford Oxford United Kingdom
-
- H.B. Bueno‐de‐Mesquita
- Department of Epidemiology and Biostatistics School of Public Health Imperial College London United Kingdom
-
- E. Riboli
- Department of Epidemiology and Biostatistics School of Public Health Imperial College London United Kingdom
-
- P. Vineis
- MRC‐PHE Center for Environment and Health School of Public Health Imperial College London United Kingdom
-
- I. Romieu
- International Agency for Research on Cancer Lyon France
-
- M.J. Gunter
- International Agency for Research on Cancer Lyon France
-
- V. Chajès
- International Agency for Research on Cancer Lyon France
Abstract
<jats:p>There are both limited and conflicting data on the role of dietary fat and specific fatty acids in the development of pancreatic cancer. In this study, we investigated the association between plasma phospholipid fatty acids and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. The fatty acid composition was measured by gas chromatography in plasma samples collected at recruitment from375 incident pancreatic cancer cases and375 matched controls. Associations of specific fatty acids with pancreatic cancer risk were evaluated using multivariable conditional logistic regression models with adjustment for established pancreatic cancer risk factors. Statistically significant inverse associations were found between pancreatic cancer incidence and levels of heptadecanoic acid (OR<jats:sub>T3‐T1</jats:sub>[odds ratio for highest versus lowest tertile] =0.63; 95%CI[confidence interval] = 0.41–0.98; <jats:italic>p</jats:italic><jats:sub>trend</jats:sub> = 0.036), n‐3 polyunsaturated α‐linolenic acid (OR<jats:sub>T3‐T1</jats:sub> = 0.60; 95%CI = 0.39–0.92; <jats:italic>p</jats:italic><jats:sub>trend</jats:sub> = 0.02) and docosapentaenoic acid (OR<jats:sub>T3‐T1</jats:sub> = 0.52; 95%CI = 0.32–0.85; <jats:italic>p</jats:italic><jats:sub>trend</jats:sub> = 0.008). Industrial trans‐fatty acids were positively associated with pancreatic cancer risk among men (OR<jats:sub>T3‐T1</jats:sub> = 3.00; 95%CI = 1.13–7.99; <jats:italic>p</jats:italic><jats:sub>trend</jats:sub> = 0.029), while conjugated linoleic acids were inversely related to pancreatic cancer among women only (OR<jats:sub>T3‐T1</jats:sub> = 0.37; 95%CI = 0.17–0.81; <jats:italic>p</jats:italic><jats:sub>trend</jats:sub> = 0.008). Among current smokers, the long‐chain n‐6/n‐3 polyunsaturated fatty acids ratio was positively associated with pancreatic cancer risk (OR<jats:sub>T3‐T1</jats:sub> = 3.40; 95%CI = 1.39–8.34; <jats:italic>p</jats:italic><jats:sub>trend</jats:sub> = 0.007). Results were robust to a range of sensitivity analyses. Our findings suggest that higher circulating levels of saturated fatty acids with an odd number of carbon atoms and n‐3 polyunsaturated fatty acids may be related to lower risk of pancreatic cancer. The influence of some fatty acids on the development of pancreatic cancer may be sex‐specific and modulated by smoking.</jats:p>
Journal
-
- International Journal of Cancer
-
International Journal of Cancer 143 (10), 2437-2448, 2018-09-21
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360857597185164288
-
- ISSN
- 10970215
- 00207136
-
- Data Source
-
- Crossref